Moderna’s concerns about Omicron outlook spark market slump | Business Standard News

At a time of uncertainty about omicron’s impact on the pandemic’s course and world economies, the comments fueled a new round of concern.

The companies that bet on messenger RNA vaccines — BioNTech SE and its partner Pfizer Inc.

But the new variant could offer Moderna a chance to catch up to the Pfizer-BioNTech effort, whose shot has turned into the best-selling pharmaceutical product of all time.

Other vaccine makers including AstraZeneca Plc, Johnson & Johnson, Sinovac Biotech Ltd, CanSino Biologics Inc.

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world.

…Read the full story